Das Zentrum
Multiple Sklerose Zentrum Dresden
Patienteninformation
Kontaktinformation
Behandlungsteam
Studienteam
Neuropsychologie
Mobilitätszentrum
Das Mobilitätszentrum
Ganganalyse
Sprunganalyse
DIERS
EMIQ
Forschungsprojekte
Neuroimmunologisches Labor
Das NIL
Neurofilament-Leichtketten Analyse
Autonomes & Neuroendokrinologisches Funktionslabor
Das ANF
Untersuchungsmethoden
MS Living Lab
Management & Science
Team Management & Science
Projekte
eHealth & Analytics
MSDS 3D
MSDS Klinik & Praxis
MS-HRS
MTRS
MS Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immunzellkalender 2025
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
Deutsch
Deutsch
English
Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab
MS Treatments
Jahr
Publikationsjahr
2024
Autoren
Autorenliste der Publikation
Hersh CM, Pang M, Miller DM, McGinley MP, Hyland M, Ziemssen T, Avila RL.
Verlag
Publisher-Information
Neurodegener Dis Manag. 2024 Apr 16.
Link
Zur Publikation (externer Server)
https://doi.org/10.2217/nmt-2023-0047
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
MSZ
Treatments
2024
Ziemssen T, Centonze D. Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing. Mult Scler. 2025 Jun;31(7):751-753. doi: 10.1177/13524585251346658. Epub 2025 Jun 14. PMID: 40515640.
MS Treatments
Jahr
2025
Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study
MASC
Jahr
2025
CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany
MS Treatments
Jahr
2025
RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis
MASC
Jahr
2025
Experiences of People with Multiple Sclerosis in Sensor-Based Jump Assessment
Mobility
Jahr
2025
